Gilead Sciences, Inc. (GILD) Financials
GILD Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2024-03-31 | 56.3 billion | 38.8 billion |
| 2023-12-31 | 62.1 billion | 39.4 billion |
| 2023-09-30 | 62.4 billion | 40.1 billion |
| 2023-06-30 | 62.3 billion | 41.2 billion |
GILD Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2024-03-31 | 2.1 billion | 187.0 million |
| 2023-12-31 | 2.0 billion | 201.0 million |
| 2023-09-30 | 1.6 billion | 202.0 million |
| 2023-06-30 | 2.2 billion | 198.0 million |
GILD Net Income
| Date | Net Income |
|---|---|
| 2024-03-31 | -4.2 billion |
| 2023-12-31 | 1.4 billion |
| 2023-09-30 | 2.2 billion |
| 2023-06-30 | 1.0 billion |
GILD Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2024-03-31 | 6.1 billion | - | - |
| 2023-12-31 | 8.4 billion | - | - |
| 2023-09-30 | 8.0 billion | - | - |
| 2023-06-30 | 8.0 billion | 21.2 billion | - |
GILD Shares Outstanding
GILD Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2024-03-31 | 105.0 million | 1.5 billion | 1.4 billion | - |
| 2023-12-31 | 215.0 million | 1.5 billion | 771.0 million | 826.0 million |
| 2023-09-30 | 122.0 million | 1.5 billion | 1.3 billion | - |
| 2023-06-30 | 139.0 million | 1.4 billion | 1.8 billion | - |
GILD Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2024-03-31 | 6.7 billion | 1.6 billion |
| 2023-12-31 | 7.1 billion | 1.6 billion |
| 2023-09-30 | 7.1 billion | 1.6 billion |
| 2023-06-30 | 6.6 billion | 1.4 billion |
GILD
List: Challengers
Price: $67.90
Dividend Yield: 4.67%
Forward Dividend Yield: 4.55%
Payout Ratio: 68.44%
Dividend Per Share: 3.08 USD
Earnings Per Share: 0.36 USD
P/E Ratio: 15.59
Exchange: NMS
Sector: Healthcare
Industry: Drug Manufacturers - General
Volume: 2.7 million
Ebitda: 2.4 billionMarket Capitalization: 82.2 billion
Average Dividend Frequency: 4
Years Paying Dividends: 10
DGR3: 3.21%
DGR5: 5.30%